<DOC>
	<DOC>NCT02707653</DOC>
	<brief_summary>This study will investigate the use of misoprostol for first-line treatment of incomplete abortion at tertiary hospitals in Myanmar.</brief_summary>
	<brief_title>Sublingual Misoprostol for the Treatment of Incomplete Abortion: Operations Research</brief_title>
	<detailed_description>This open-label feasibility study seeks to examine the potential of 400Î¼g sublingual misoprostol for the treatment of incomplete abortion provided at tertiary hospitals.</detailed_description>
	<mesh_term>Abortion, Incomplete</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>1. Confirmed incomplete abortion 2. No known contraindications to the study drug 3. Uterine size no larger than 12 weeks at time of presentation for care 4. No signs of severe infection, defined as at least two of the following: foul smelling discharge, fever &gt; 38 degrees C, 100 degrees Fahrenheit uterine tenderness. 5. No hemodynamic disturbances (pulse &gt;110/min and systolic bp &lt;100) 6. General good health 7. Agree to comply with study procedures including return for follow up visit 8. Live or work within one hour from a study site 9. Willing and able to sign consent forms 1. Inability to provide informed consent</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>